What's Happening?
SK Capital Partners has completed the sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG, a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry. The transaction allows SK Capital to retain
ownership of Halo Pharmaceuticals, which will continue to operate independently with a focus on expanding its capabilities, including launching sterile injectable manufacturing. The leadership team of Noramco, including CEO Lee Karras and CFO Alan Majewski, will remain with Halo Pharmaceuticals to guide its growth.
Why It's Important?
This sale marks a strategic shift for SK Capital Partners, allowing them to concentrate on Halo Pharmaceuticals' growth and development. By focusing on expanding capabilities such as sterile injectable manufacturing, Halo Pharmaceuticals aims to meet evolving customer needs and strengthen its position in the pharmaceutical manufacturing sector. The transaction also reflects the ongoing trend of consolidation in the pharmaceutical industry, as companies seek to enhance their service offerings and market reach. For Siegfried Holding AG, acquiring Noramco and its related entities enhances its portfolio and strengthens its position as a leading CDMO.
